



## **Piroxicam**

**Catalog No: tcsc2233** 

Available Sizes
Size: 1g
Size: <sup>5</sup> g
Size: 10g
Specifications
CAS No: 36322-90-4
Formula: C <sub>15</sub> H <sub>13</sub> N <sub>3</sub> O <sub>4</sub> S
Pathway: mmunology/Inflammation
<b>Farget:</b> COX
Purity / Grade: >98%
<b>Solubility:</b> DMSO : 50 mg/mL (150.90 mM; Need ultrasonic); H2O :
Alternative Names: CP-16171
Observed Molecular Weight:

## **Product Description**





Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a **COX** inhibitor, with  $IC_{50}$ s of 47, 25  $\mu$ M for human monocyte COX-1 and COX-2, respectively.

IC50 & Target: IC50: 47 μM (COX-1, in human monocytes), 25 μM (COX-2, human monocytes)<sup>[1]</sup>

In Vitro: Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC $_{50}$ s of 47, 25  $\mu$ M for human monocyte COX-1 and COX-2, respectively<sup>[1]</sup>. Piroxicam (167, 333, 500  $\mu$ M) decreases cell population of T24 and the 5637 cells. Piroxicam (500  $\mu$ M) also reduces the cell viability of T24 and 5637 cell, and is significantly effective when combined with 0.05  $\mu$ M carboplatin. The combination also inhibits Ki-67 expression in booth cells<sup>[3]</sup>.

*In Vivo:* Piroxicam (0.3 mg/kg qd 24-h p.o.) reduces tumor volume in 12 of 18 dogs, and such and effect is via induction of apoptosis and reduction in urine basic fibroblast growth factor concentration<sup>[2]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!